
    
      This is an observational, non-interventional, prospective study in participants with
      CD30-positive lymphoma who are receiving or will receive the standard treatment of
      brentuximab vedotin. This study will assess the safety profile and effectiveness of
      brentuximab vedotin in the real-world clinical practice.

      The study will enroll approximately 1000 participants. The data will be collected and
      recorded in the medical record for the purpose of medical care and also recorded in
      electronic case report forms (e-CRFs). All the participants will be assigned to a single
      observational cohort:

      â€¢ All participants with CD30-positive lymphoma

      This multi-center trial will be conducted in China. All participants will be followed up for
      24 months unless withdrawal of Informed Consent, lost or death, whichever comes first. The
      overall duration of the study will be approximately 4 years.
    
  